]>
IRCT2017092836204N2 IRCT 2017-10-25 Vice chancellor for research, Shiraz University of Medical Sciences Effect of Menaquinone supplementation on insulin resistance, lipid profile, anthropometric measurments, endocrine markers and oxidative stress in patients with polycystic ovary syndrome who will be referred to health centers of Shiraz University of Medical Sciences, 1396. Effect of Menaquinone supplementation on insulin resistance, lipid profile, anthropometric measurments, endocrine markers and oxidative stress in patients with polycystic ovary syndrome who will be referred to health centers of Shiraz University of Medical Sciences, 1396. 2017-06-22 anticipated 84 Complete https://irct.ir/trial/27134 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive. 2-3 polycystic ovary syndrome. Intervention 1: Intervention group: 1 capsule containing 90 micrograms of menaquinone per day for 8 weeks. Intervention 2: Control group: 1 placebo capsule containing avesil per day for 8 weeks.
public Firoozeh Tarkesh
Department of Nutrition and Food Science, Fatholmobin alley, Razi blvd
Shiraz Iran (Islamic Republic of) +98 71 3725 1001 firoozeh_tarkesh@yahoo.com Shiraz University of Medical Sciences, Faculty of Nutrition and Food Sciences scientific Najmeh Hejazi
Department of Nutrition and Food Science, Fatholmobin alley, Razi blvd
Shiraz Iran (Islamic Republic of) +98 71 3725 1001 Nhejazi@sums.ac.ir Shiraz University of Medical Sciences, Faculty of Nutrition and Food Sciences Iran (Islamic Republic of) Inclusion criteria: Suffering from polycystic ovary syndrome based on Rotterdam criteria; age between 18 to 40 ; absecnce of pregnancy or lactation; absence of antidiabetic, antihypertensive, antihyperlipidemic, anticoagulant treatment; absence of using metformin 2 months before entering the study and during the intervention; acute or chronic inflammation; absence of any current diet or supplement treatment; absence of antidiabetic, antihypertensive, antihyperlipidemic treatment; absence of using drugs effective on bone metabolism; any disease or physiological changes that requires special treatment; nonsmoker, nonalcoholic. Exclusion criteria: Unwillingness to continue; any disease or physiological changes that requires special treatment; failure to follow the intervention designing (not consuming dedicated supplement to the total amount less than 90% predicted or more than 3 days). 18 years 40 years Female E28.2 polycystic ovarian syndrome Treatment - Drugs Placebo Intervention group: 1 capsule containing 90 micrograms of menaquinone per day for 8 weeks Control group: 1 placebo capsule containing avesil per day for 8 weeks Fasting blood sugar. Timepoint: Before and after intervention. Method of measurement: auto analyser. Dehydroepiandrosterone Sulfate (DHEAS). Timepoint: Before and after intervention. Method of measurement: ELISA kit. Total testosterone. Timepoint: Before and after intervention. Method of measurement: ELISA kit. Malondialdehyde (MDA). Timepoint: Befor and after intervention. Method of measurement: Spectrophotometry. Dihydrotestosterone (DHT). Timepoint: Before and after intervention. Method of measurement: ELISA kit. Sex Hormone Binding Globulin (SHBG). Timepoint: Before and after intervention. Method of measurement: ELISA kit. Lipid profile (TG, Cholesterol, HDL, LDL). Timepoint: Before and after intervention. Method of measurement: auto analyser. Fasting insulin. Timepoint: Before and after intervention. Method of measurement: ELISA kit. - - Vice chancellor for research, Shiraz University of Medical Sciences Approved 2017-04-17 Ethics committee of Shiraz University of Medical Sciences Shiraz University of Medical Sciences, Zand street Shiraz Iran (Islamic Republic of)